Yükleniyor... / Loading...
This study investigated the relationship between cancer treatment and hearing loss, and its genetic basis, in children who had previously received cisplatin or carboplatin. It included children aged 4 and older who had an audiogram for each ear and whose parents gave consent. It was a study with no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * previous treatment with cis-or carboplatin * Age equal to or greater than 4 years * the presence of a separate complete audiogram for each ear in order to define the Brock grade * informed and written consent of both parents or legal guardian * affiliation of the child to a social security scheme To patients: * previous treatment with platinum compounds for neuroblastoma, hepatoblastoma, pancreatoblastoma, retinoblastoma, germ cell tumor malignant osteosarcoma, Wilms high risk or relapsed non para-meningeal rhabdomyosarcoma with ototoxicity grade 3 or 4 Brock (Grade 3 - 40dB to 2000 Hz; Grade 4-40 dB at 1000 Hz) To patients controls * previous treatment with platinum compounds for neuroblastoma, hepatoblastoma, pancreatoblastoma, retinoblastoma, germ cell tumor malignant osteosarcoma, Wilms high risk or recurrence rhabdomyosarcoma non parameningeal without ototoxicity (grade 0 Brock) * minimum follow-up of 3 years after stopping treatment Exclusion Criteria: * patients with brain tumor * patients with tumor "paraméningée" (such as rhabdomyosarcoma of the rock) * patients with renal toxicity (≥ Grade 2) at the time of treatment with platinum-based * patients with pathological pre-treatment assessment of hearing * chemotherapy during * patients with cerebral or total body irradiation (Total Body Irradiation)